stockrowBoston Scientific Corporation
BSX Healthcare Medical Devices
Boston Scientific Corporation’s revenue for fiscal 2025 (year ended December 2025) was $20.1 billion, up 19.9% from fiscal 2024.
- Revenue
- +1.44%
- EPS
- −21.6%
- Free cash flow
- −25.3%
- Total debt
- +3.04%
Quarter to September 2026, against a year earlier
Follow BSX
Alert me
Boston Scientific Corporation (BSX) P/S ratio
As of 5 November 2026, Boston Scientific Corporation (BSX) trades at a P/S ratio of 3.1×. Over the past ten years it has ranged from 2.4× (January 2015) to 9.3× (February 2025); the current reading is higher than 4% of that period. That is above the Medical Devices industry median of 2.5× and below the Healthcare sector median of 3.5×.
P/S ratio, daily
Embed this chart
Annual newest first
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 7.0× | (10.40%) |
| FY2024 | 7.8× | 32.98% |
| FY2023 | 5.9× | 13.72% |
| FY2022 | 5.2× | 2.11% |
| FY2021 | 5.1× | (1.08%) |
| FY2020 | 5.1× | (12.35%) |
| FY2019 | 5.9× | 17.98% |
| FY2018 | 5.0× | 29.79% |
| FY2017 | 3.8× | 8.07% |
| FY2016 | 3.5× | 7.09% |
Quarterly newest first
| Period | P/S ratio | Change |
|---|---|---|
| Sep 2026 | 3.0× | 0.43% |
| Jun 2026 | 3.0× | (33.88%) |
| Mar 2026 | 4.5× | (35.72%) |
| Dec 2025 | 7.0× | (5.94%) |
| 43 more quarters | Free account |
Against its own ten years
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| PHG Koninklijke Philips N.V. compare | 1.4× |
| GEHC GE HealthCare Technologies Inc. compare | 1.7× |
| BSX Boston Scientific Corporation | 3.1× |
| MDT Medtronic PLC compare | 3.6× |
| STE STERIS plc compare | 4.0× |
| ABT Abbott Laboratories compare | 4.1× |
| SYK Stryker Corporation compare | 4.9× |
| DXCM DexCom, Inc. compare | 6.2× |
| EW Edwards Lifesciences Corporation compare | 8.7× |
| Medical Devices industry median | 2.5× |
| Healthcare sector median | 3.5× |
| Market median | 1.9× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on BSX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement